EGFR and non-small cell lung carcinoma: We have previously reported that the generation EGFR-TKI used was associated with therapeutic efficacy in EGFR-mutant NSCLC patients, in which gefitinib/erlotinib-treated patients presented a shorter PFS compared to afatinib-treated ones11.